Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Somatic mutations in cancer cells create neoantigens, which are presented to the immune system.
• Tumor neoantigens are specific to cancer tissue, making them ideal immunotherapy targets.
• Direct evidence of neoantigen-specific T-cell responses in multiple myeloma was lacking despite immunotherapy use.

Purpose of the Study:

• To investigate the landscape of neoantigens in multiple myeloma.
• To validate neoantigen-specific T-cell responses in multiple myeloma patients.
• To assess the feasibility of neoantigen-based therapeutic vaccines for multiple myeloma.

Main Methods:

• Analysis of next-generation sequencing data from 184 multiple myeloma patients.
• Validation of neoantigen-specific T cells.
• Correlation of T-cell response and clonal expansion with clinical outcomes.

Main Results:

• Neoantigen load is increased in relapsed multiple myeloma compared to newly diagnosed.
• Shared neoantigens were identified in key multiple myeloma driver genes (KRAS, NRAS, IRF4).
• Neoantigen immunogenicity and T-cell activation correlated with antitumor activity and clinical response.

Conclusions:

• Somatic mutations in multiple myeloma are immunogenic, inducing neoantigen-specific T-cell activation.
• Neoantigen-specific T-cell responses are associated with antitumor activity and clinical response.
• Findings support neoantigen targeting strategies, like peptide vaccines, for future multiple myeloma trials.